312 related articles for article (PubMed ID: 18379537)
21. Vasoactive components of dialysis solution.
Zakaria el R; Patel AA; Li N; Matheson PJ; Garrison RN
Perit Dial Int; 2008; 28(3):283-95. PubMed ID: 18474922
[TBL] [Abstract][Full Text] [Related]
22. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
[TBL] [Abstract][Full Text] [Related]
23. Effects of Icodextrin and Glucose Bicarbonate/Lactate-Buffered Peritoneal Dialysis Fluids on Effluent Cell Population and Biocompatibility Markers IL-6 and CA125 in Incident Peritoneal Dialysis Patients.
Opatrná S; Pöpperlová A; Lysák D; Fuchsová R; Trefil L; Racek J; Topolčan O
Ther Apher Dial; 2016 Apr; 20(2):149-57. PubMed ID: 26929256
[TBL] [Abstract][Full Text] [Related]
24. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
Opatrna S; Lysak D; Trefil L; Parker C; Topley N
Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
[TBL] [Abstract][Full Text] [Related]
25. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation.
Ha H; Yu MR; Choi HN; Cha MK; Kang HS; Kim MH; Lee HB
Perit Dial Int; 2000; 20 Suppl 5():S10-8. PubMed ID: 11229606
[TBL] [Abstract][Full Text] [Related]
26. Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation.
Yamaguchi N; Miyamoto K; Murata T; Ishikawa E; Horiuchi T
Artif Organs; 2016 Aug; 40(8):E158-66. PubMed ID: 27530675
[TBL] [Abstract][Full Text] [Related]
27. Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers.
Yung S; Lui SL; Ng CK; Yim A; Ma MK; Lo KY; Chow CC; Chu KH; Chak WL; Lam MF; Yung CY; Yip TP; Wong S; Tang CS; Ng FS; Chan TM
Perit Dial Int; 2015; 35(2):147-58. PubMed ID: 25904773
[TBL] [Abstract][Full Text] [Related]
28. Three-pore model predictions of 24-hour automated peritoneal dialysis therapy using bimodal solutions.
Akonur A; Leypoldt JK
Perit Dial Int; 2011; 31(5):537-44. PubMed ID: 21632445
[TBL] [Abstract][Full Text] [Related]
29. A randomized clinical trial with a 0.6% amino acid/ 1.4% glycerol peritoneal dialysis solution.
Van Biesen W; Boer W; De Greve B; Dequidt C; Vijt D; Faict D; Lameire N
Perit Dial Int; 2004; 24(3):222-30. PubMed ID: 15185770
[TBL] [Abstract][Full Text] [Related]
30. Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral blood mononuclear cell and polymorphonuclear cell function in vitro.
Sundaram S; Cendoroglo M; Cooker LA; Jaber BL; Faict D; Holmes CJ; Pereira BJ
Am J Kidney Dis; 1997 Nov; 30(5):680-9. PubMed ID: 9370184
[TBL] [Abstract][Full Text] [Related]
31. Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials.
Goossen K; Becker M; Marshall MR; Bühn S; Breuing J; Firanek CA; Hess S; Nariai H; Sloand JA; Yao Q; Chang TI; Chen J; Paniagua R; Takatori Y; Wada J; Pieper D
Am J Kidney Dis; 2020 Jun; 75(6):830-846. PubMed ID: 32033860
[TBL] [Abstract][Full Text] [Related]
32. Studying the effects of new peritoneal dialysis solutions on the peritoneum.
Chan TM; Yung S
Perit Dial Int; 2007 Jun; 27 Suppl 2():S87-93. PubMed ID: 17556337
[TBL] [Abstract][Full Text] [Related]
33. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model.
Mortier S; Faict D; Lameire NH; De Vriese AS
Kidney Int; 2005 Apr; 67(4):1559-65. PubMed ID: 15780112
[TBL] [Abstract][Full Text] [Related]
34. Update on peritoneal dialysis solutions.
McIntyre CW
Kidney Int; 2007 Mar; 71(6):486-90. PubMed ID: 17299524
[TBL] [Abstract][Full Text] [Related]
35. Stability and Compatibility of Antibiotics in Peritoneal Dialysis Solutions Applied to Automated Peritoneal Dialysis in The Pediatric Population.
Deslandes G; Grégoire M; Bouquié R; Le Marec A; Allard S; Dailly E; Pineau A; Allain-Launay E; Jolliet P; Roussey G; Navas D
Perit Dial Int; 2016 11-12; 36(6):676-679. PubMed ID: 27147292
[TBL] [Abstract][Full Text] [Related]
36. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.
le Poole CY; van Ittersum FJ; Weijmer MC; Valentijn RM; ter Wee PM
Adv Perit Dial; 2004; 20():170-6. PubMed ID: 15384821
[TBL] [Abstract][Full Text] [Related]
37. Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane.
Mortier S; Faict D; Gericke M; Lameire N; De Vriese A
Nephron Exp Nephrol; 2005; 101(4):e139-45. PubMed ID: 16131808
[TBL] [Abstract][Full Text] [Related]
38. Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature.
Dousdampanis P; Trigka K; Chu M; Khan S; Venturoli D; Oreopoulos DG; Bargman JM
Int Urol Nephrol; 2011 Mar; 43(1):203-9. PubMed ID: 20953705
[TBL] [Abstract][Full Text] [Related]
39. [Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].
Haag-Weber M
Wien Klin Wochenschr; 2005; 117 Suppl 6():89-97. PubMed ID: 16437339
[TBL] [Abstract][Full Text] [Related]
40. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
